Lapatinib-capecitabine versus capecitabine alone as radiosensitizers in RAS wild-type resectable rectal cancer, an adaptive randomized phase II trial (LaRRC trial): study protocol for a randomized controlled trial
Crossref DOI link: https://doi.org/10.1186/s13063-016-1583-y
Published Online: 2016-09-21
Published Print: 2016-12
Update policy: https://doi.org/10.1007/springer_crossmark_policy
Sousa, Nuno
Sousa, Olga
Santos, Lúcio Lara
Henrique, Rui
Teixeira, Manuel R.
Dinis-Ribeiro, Mário
Teixeira-Pinto, Armando